WallStSmart

Akso Health Group ADR (AHG)vsEDAP TMS SA (EDAP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

EDAP TMS SA generates 436% more annual revenue ($74.07M vs $13.83M). EDAP leads profitability with a -41.7% profit margin vs -135.0%. EDAP earns a higher WallStSmart Score of 25/100 (F).

AHG

Avoid

15

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.3Quality: 9.0
Piotroski: 5/9Altman Z: 12.00

EDAP

Avoid

25

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHGUndervalued (+10.2%)

Margin of Safety

+10.2%

Fair Value

$1.57

Current Price

$0.84

$0.73 discount

UndervaluedFair: $1.57Overvalued
EDAPUndervalued (+41.7%)

Margin of Safety

+41.7%

Fair Value

$8.41

Current Price

$4.31

$4.10 discount

UndervaluedFair: $8.41Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
12.0010/10

Safe zone — low bankruptcy risk

EDAP0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AHG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$625.57M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-89.4%2/10

ROE of -89.4% — below average capital efficiency

Revenue GrowthGrowth
-12.9%2/10

Revenue declined 12.9%

EDAP4 concerns · Avg: 2.8/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

Market CapQuality
$156.30M3/10

Smaller company, higher risk/reward

PEG RatioValuation
90.472/10

Expensive relative to growth rate

Return on EquityProfitability
-124.0%2/10

ROE of -124.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.

Bull Case : EDAP

Revenue growth of 13.9% demonstrates continued momentum.

Bear Case : AHG

The primary concerns for AHG are EPS Growth, Market Cap, Return on Equity.

Bear Case : EDAP

The primary concerns for EDAP are Price/Book, Market Cap, PEG Ratio.

Key Dynamics to Monitor

EDAP carries more volatility with a beta of -0.10 — expect wider price swings.

EDAP is growing revenue faster at 13.9% — sustainability is the question.

EDAP generates stronger free cash flow (-4M), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EDAP scores higher overall (25/100 vs 15/100) and 13.9% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, dedicated to providing innovative medical solutions and comprehensive patient care services. With a strong emphasis on advanced health technologies, the company is strategically positioned in the telehealth and personalized medicine markets, supported by a robust research and development framework. As it navigates the rapidly evolving healthcare landscape, Akso Health Group presents an attractive investment opportunity for institutional investors seeking to capitalize on transformative trends within the industry.

Visit Website →

EDAP TMS SA

HEALTHCARE · MEDICAL DISTRIBUTION · USA

EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.

Want to dig deeper into these stocks?